Analysis-Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom

Novo Nordisk, having aggressively expanded its workforce to 77,350 employees over five years to support Wegovy's growth, now faces significant cost pressures and potential layoffs as sales slow and competition from Eli Lilly's Zepbound intensifies. This rapid hiring nearly doubled employee costs to $9.9 billion, squeezing gross margins and contributing to a $490 billion market capitalization decline. New CEO Maziar Mike Doustdar has since implemented a global hiring freeze and signaled comprehensive cost-cutting measures, including potential workforce reductions, to address the company's prior 'complacent' expansion and restore profitability.

Analysis

Novo Nordisk is undergoing a significant strategic pivot from hyper-growth to aggressive cost rationalization, driven by slowing sales of its blockbuster drug Wegovy and intensifying competition from Eli Lilly's Zepbound. The company's workforce nearly doubled to 77,350 over five years, a rate far exceeding its rival, which inflated employee costs to almost $9.9 billion and compressed its gross margin to a two-and-a-half-year low in the second quarter. This operational bloat, described by one investor as a sign of complacency, has contributed to two profit warnings this year and a $490 billion erosion in market capitalization from its peak. In response, the new CEO has initiated a global hiring freeze for non-critical roles and signaled comprehensive cost-cutting measures, with potential layoffs looming. Analysts and former employees suggest the sales division, which saw duplicated efforts, and administrative functions are likely targets for reduction, as the company seeks to streamline an organization that reportedly became difficult to manage during its rapid expansion.

Key Decisions for Investors

• Investors in Novo Nordisk should closely monitor management's execution on its cost-cutting plan and its impact on gross margins, as the company's ability to restore profitability amidst competitive pressure is now the primary catalyst for the stock.
• The article positions Eli Lilly as a direct beneficiary of Novo's challenges, suggesting a potential pairs trade or a portfolio re-weighting in favor of LLY, which has demonstrated more measured expansion and is gaining market share.
• Pay close attention to any specific announcements regarding the scale of workforce reductions, as this will be a key indicator of the new CEO's commitment to addressing the operational inefficiencies and cost structure that developed during the recent hiring spree.
• Consider the execution risk associated with a rapid shift from growth to austerity, as potential disruptions to operations and employee morale could hinder Novo's ability to effectively compete and defend its market position in the near term.